tiprankstipranks
Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer’s disease
The Fly

Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer’s disease

Eisai (ESALY) and Biogen (BIIB) announced that the European Medicines Agency has accepted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril antibody, for the treatment of early Alzheimer’s disease with confirmed amyloid pathology, for review following a standard timeline.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on BIIB:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles